Compare MXF & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MXF | ELDN |
|---|---|---|
| Founded | N/A | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.9M | 291.8M |
| IPO Year | 1995 | 2014 |
| Metric | MXF | ELDN |
|---|---|---|
| Price | $21.82 | $3.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 30.5K | ★ 932.4K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.81 | $1.35 |
| 52 Week High | $23.00 | $4.60 |
| Indicator | MXF | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 54.53 | 39.68 |
| Support Level | $20.96 | $3.31 |
| Resistance Level | $22.31 | $4.02 |
| Average True Range (ATR) | 0.50 | 0.18 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 56.67 | 21.14 |
Mexico Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation. The fund seeks to achieve its objective through investment in securities, primary in equity, listed on the Mexican Stock Exchange. The company's portfolio of investments consists of investments in different sectors such as auto parts, airports, building materials, chemical products, consumer products, energy, food, and other sectors. The fund provides a vehicle to investors who wish to invest in Mexican companies through a managed non-diversified portfolio as part of their overall investment program.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.